NDAORALTABLET
Approved
Mar 1960
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 8h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NAQUA (trichlormethiazide) is an oral thiazide diuretic approved in 1960 for the treatment of hypertension and edema. It works by inhibiting sodium reabsorption in the distal convoluted tubule, promoting fluid and sodium excretion. This product represents a legacy small-molecule therapeutic in the cardiovascular class.
LOE Approaching
This legacy product is approaching loss of exclusivity with minimal commercial investment; career growth opportunities are limited to defensive maintenance roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on NAQUA offers limited career growth due to its LOE-approaching status and zero linked job postings. This role is best suited for professionals seeking defensive commercial work or those transitioning toward portfolio management of legacy products.
Brand ManagerField Sales Representative
Worked on NAQUA at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.